Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1651 1657 1692
This examiner grants 70% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18294902 | Compositions, Systems and Methods for Atom Transfer Radical Addition Reaction | Non-Final OA | The Regents of the University of California |
| 18268177 | MEANS AND METHODS FOR MANUFACTURING RACEMIC ALANINE FOR THE MGDA SYNTHESIS | Non-Final OA | BASF SE |
| 18236366 | TRAINED NEURONAL CELL CULTURES FOR DRUG TESTING | Non-Final OA | MICROSOFT TECHNOLOGY LICENSING, LLC |
| 18284239 | COMPOSITION FOR ENHANCING PHYSIOLOGICAL EFFICACY OF LACTIC ACID BACTERIA | Final Rejection | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION |
| 17600931 | DUAL ANTIGEN-RECOGNIZING iPS CELL-DERIVED CHIMERIC ANTIGEN RECEPTOR-T-CELL THERAPY | Non-Final OA | THE UNIVERSITY OF TOKYO |
| 18690537 | POLYSACCHARIDE OR POLYSACCHARIDE MIXTURE PRODUCED BY PAENIBACILLUS POLYMYXA | Non-Final OA | Technische Universität München |
| 18775257 | HUMAN IPSC-DERIVED VASCULAR-RELATED AND HEMATOPOETIC CELLS FOR THERAPIES AND TOXICOLOGY/DRUG SCREENINGS | Final Rejection | The USA, as represented by the Secretary, Department of Health and Human Services |
| 18621330 | NOVEL PROTEASES AND USES THEREOF | Non-Final OA | CARBIOS |
| 18546864 | DNASE 1-LIKE 2 ENGINEERED FOR MANUFACTURING AND USE IN THERAPY | Non-Final OA | Neutrolis, Inc |
| 18451280 | CELL PENETRATING PEPTIDE, CONJUGATE COMPRISING SAME, AND COMPOSITION COMPRISING CONJUGATE | Non-Final OA | GemVax & KAEL CO., LTD. |
| 17789378 | APPLICATION OF CST1 IN PREVENTION AND/OR TREATMENT OF LIVER IMMUNE DYSREGULATION DISEASES | Non-Final OA | CENTER FOR EXCELLENCE IN MOLECULAR CELL SCIENCE, CHINESE ACADEMY OF SCIENCES |
| 18330510 | CORNEAL ENDOTHELIUM ECM THERAPEUTIC MEDICAMENTS | Final Rejection | SENJU PHARMACEUTICAL CO., LTD. |
| 18035549 | METHODS FOR SYSTEMATICALLY ASSESSING LOCAL INFLAMMATION AND ACTIVE REPAIR | Non-Final OA | KEYINTEL MEDICAL INC. |
| 17747468 | Inhibitors of DREAM Complex Assembly and/or Function For Use In Repairing DNA Damage | Non-Final OA | Björn Schumacher |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy